李氏大藥廠(00950.HK):擬分拆COPFL獨立上市
格隆匯 7 月 9日丨李氏大藥廠(00950.HK)宣佈,公司正考慮可能分拆COPFL(為公司間接非全資附屬公司)及於認可證券交易所將其股份獨立上市。
COPFL及其附屬公司專門從事眼科藥品的開發、製造及營銷。COPFL已透過其全資附屬公司兆科(廣州)眼科藥物有限公司於廣州南沙建立尖端開發及生產設施。該設施支援21種以上專利產品以及高端仿製藥(從臨牀前到註冊階段不等)之內部開發及日後商品化,行銷中國市場。其產品組合多樣化,包括小分子及生物製劑,亦包括新藥及仿製藥,涵蓋乾眼、青光眼、濕性老年性黃斑部病變、糖尿病性視網膜病變以至角膜損傷及炎症疾病等各種眼科適應症。集團其中一項重點產品環孢黴素A眼凝膠已進入關鍵的第三期臨牀測試,涵蓋中國40個臨牀測試中心,目標招募合共644名病人。首名病人預計於2020年第三季度末前招募。環孢黴素A眼凝膠第二期測試之試驗數據顯示,環孢黴素A眼凝膠相比市場上的乳劑配方有類似或可能有更佳效能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.